Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334232 | 1.00 | ALDH1A1 (0.50) | ALDH1A1GAAELOVL1HSP90AA1MAPT | |
| SCHEMBL13224056 | 1.00 | ALDH1A1 (0.50) | ALDH1A1GAAELOVL1HSP90AA1MAPT | |
| SCHEMBL20849994 | 0.85 | ATM (0.43) | ALDH1A1GAAELOVL1HSP90AA1MAPT | |
| SCHEMBL19578343 | 0.85 | ALDH1A1 (0.44) | ALDH1A1GAAELOVL1AOC3KDM4E | |
| SCHEMBL20849754 | 0.84 | MTOR (0.41) | ALDH1A1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL8910235 | 0.82 | OPRM1 (0.43) | ALDH1A1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL8908400 | 0.81 | ALDH1A1 (0.44) | ALDH1A1GAAAOC3CYP3A4 | |
| SCHEMBL8907267 | 0.81 | CYP2C19 (0.36) | ALDH1A1GAAELOVL1KDM4ECYP3A4 | |
| SCHEMBL10120515 | 0.81 | ACP3 (0.41) | ALDH1A1GAAMAPTAOC3MEN1 | |
| SCHEMBL14664133 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAAELOVL1HSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | NR1H4, HAVCR2, CYP3A4 | ALDH1A1 1071/4885GAA 2783/4885ELOVL1 3954/4885 |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885GAA 223/4885ELOVL1 1708/4885 |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALDH1A1 365/4885GAA 285/4885ELOVL1 971/4885 |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | ALDH1A1 3778/4885GAA 777/4885ELOVL1 3149/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885GAA 223/4885ELOVL1 1708/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885GAA 223/4885ELOVL1 1708/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALDH1A1 365/4885GAA 285/4885ELOVL1 971/4885 |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885GAA 223/4885ELOVL1 1708/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 229/4885GAA 701/4885ELOVL1 1278/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ALDH1A1 287/4885GAA 433/4885ELOVL1 1596/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885GAA 223/4885ELOVL1 1708/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885GAA 223/4885ELOVL1 1708/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885GAA 223/4885ELOVL1 1708/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | ALDH1A1 132/4885GAA 169/4885ELOVL1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.